Key facts
- This page summarizes Sven Dethlefs's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Mar 2023, 15:03.
Sven Dethlefs - 06 Mar 2023 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
- Reporting relationship
- EVP, North America Commercial
- Issuer ticker
- TEVA
- Reported as of
- 06 Mar 2023
- Net transaction value
- -$739,653
- SEC form
- 4
- Accepted by SEC
- 08 Mar 2023, 15:03:43 UTC
- Prior SEC filing
- 07 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dov Bergwerk as attorney-in-fact for Sven Dethlefs
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sven Dethlefs filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 08 Mar 2023.
Change
- Previous filing in this sequence was filed on 07 Mar 2023.
- Current net transaction value: -$739,653.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TEVA
transaction
Ordinary Shares
Sale
- Transaction value
- $192,213
- Shares
- -19,355
- Change %
- -8%
- Price
- $9.93
- Shares after
- 223,447
- Date
- 06 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3
TEVA
transaction
Ordinary Shares
Sale
- Transaction value
- $547,440
- Shares
- -58,066
- Change %
- -26%
- Price
- $9.43
- Shares after
- 165,381
- Date
- 07 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F2
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.